联合检测P504s和Claudin-4在前列腺癌中的表达及其在预后评估中的价值

毕罡; 毛成毅; 江军; 张尧; 张军; 龙吟

doi:10.16016/j.1000-5404.201906084

您当前的位置：

首页 >

文章列表页 >

联合检测P504s和Claudin-4在前列腺癌中的表达及其在预后评估中的价值

临床医学 | 更新时间：2026-01-09

- 联合检测P504s和Claudin-4在前列腺癌中的表达及其在预后评估中的价值
- Expression of P504s and claudin-4 in prostate cancer and prognostic value of their combined detection
- 第三军医大学学报 2019年41卷第22期页码：2195-2198
- 作者机构：
  
  1.400042 重庆, 陆军军医大学(第三军医大学)大坪医院:泌尿外科
  2.400042 重庆, 陆军军医大学(第三军医大学)大坪医院:病理科
- 作者简介：
  
  [毕罡，E-mail:29056682@qq.comBI Gang, E-mail: 29056682@qq.com
- 基金信息：
  
  重庆市自然科学基金一般项目(CSTC2014jcyjA10115)
- DOI：10.16016/j.1000-5404.201906084
  中图分类号： R730.43; R730.7; R737.25
- 收稿：2019-06-12，
  
  修回：2019-09-05，
  
  纸质出版：2019-11-30
- 稿件说明：
移动端阅览
毕罡, 毛成毅, 江军, 等. 联合检测P504s和Claudin-4在前列腺癌中的表达及其在预后评估中的价值[J]. 第三军医大学学报, 2019,41(22):2195-2198.

Gang BI, Chengyi MAO, Jun JIANG, et al. Expression of P504s and claudin-4 in prostate cancer and prognostic value of their combined detection[J]. Journal of Third Military Medical University, 2019, 41(22): 2195-2198.
毕罡, 毛成毅, 江军, 等. 联合检测P504s和Claudin-4在前列腺癌中的表达及其在预后评估中的价值[J]. 第三军医大学学报, 2019,41(22):2195-2198. DOI： 10.16016/j.1000-5404.201906084.

Gang BI, Chengyi MAO, Jun JIANG, et al. Expression of P504s and claudin-4 in prostate cancer and prognostic value of their combined detection[J]. Journal of Third Military Medical University, 2019, 41(22): 2195-2198. DOI： 10.16016/j.1000-5404.201906084.

摘要

目的

通过联合检测α-甲酰基辅酶A消旋酶(P504s)和紧密连接蛋白-4(Claudin-4)在不同危险因素等级前列腺癌中的表达，探讨P504s和Claudin-4表达在前列腺癌预后评估中的价值。

方法

选取我院病理组织库2013年1月至2015年7月的前列腺手术或穿刺标本共154例，按照病理诊断分为前列腺癌组84例，年龄52~83(70.9±7.3)岁；前列腺增生组70例，年龄51~85(68.2±7.4)岁。对2组标本组织采用组织芯片技术，构建组织芯片，S-P法检测P504s和Claudin-4蛋白的表达，并与前列腺癌预后进行相关性对比分析。

结果

P504s和Claudin-4蛋白在前列腺增生组织中的阳性表达率明显低于前列腺癌组织(

0.01)。P504s蛋白在不同Gleason评分前

列腺癌组间阳性表达率没有明显差异；在不同分期前列腺癌组间的阳性表达率亦未见明显差异。而Claudin-4蛋白在前列腺癌Gleason评分≤6分和≥7分的阳性表达率分别为60.98%和74.42%，两者间比较差异有统计学意义(

0.05)；在前列腺癌分期≤T2a期和≥T2b期的阳性表达率分别为55.26%和78.26%，两者间比较差异有统计学意义(

0.01)。

结论

P504s和Claudin-4蛋白的异常表达可能与前列腺癌的发生和进展相关，Claudin-4在危险等级越高的前列腺癌中的表达越高，联合检测可进一步提高前列腺癌的检出并对预后进行评估。

Abstract

Objective

To investigate the expression of P504s and claudin-4 in prostate cancer tissues and assess the value of their combined detection in prognostic evaluation of prostate cancer.

Methods

We analyzed a total of 154 surgical specimens or biopsy samples of prostate tissues collected between January

2013 and July

2015 in the pathological tissue bank of our hospital. These specimens

which consisted of 84 prostate cancer tissues from patients aged 52 to 83 years (mean 70.9±7.3 years) and 70 benign prostatic hyperplasia tissues from patients aged 51 to 85 years (mean 68.2±7.4 years)

were used to construct 60-dot matrix paraffin tissue chips for detection of P504s and claudin-4 proteins using immunohistochemistry with SP method. The correlation of P504s and claudin-4 expression with the prognosis of the patients with prostate cancer was analyzed.

Results

The positive expression rates of P504s and claudin-4 protein were significantly lower in benign prostatic hyperplasia tissues than in prostate cancer tissues (

0.01). The tissue microarray data did not reveal significant difference in the positive expression rate of P504s in prostate cancer tissues with different Gleason scores or in different stages. The positive expression rates of claudin-4 protein was significantly lower in prostate cancer with a Gleason score ≤6 than in that with a score ≥7 (60.98%

74.42%

0.05)

and was also lower in prostate cancer in T2a stage or lower

than that in T2b stage or higher (55.26%

78.26%

0.01).

Conclusion

Abnormal expression of P504s and claudin-4 proteins may be related with the occurrence and progression of prostate cancer

and prostate cancer with a higher level of malignancy expresses higher levels of claudin-4. Combined detection of P504s and claudin-4 can improve the detection rate of prostate cancer and can be of value in prognostic evaluation of the patients.

关键词

Keywords

references

SHOU J F, ZHANG Q, WANG S, et al . The prognosis of different distant metastases pattern in prostate cancer: A population based retrospective study[J ] . Prostate, 2018, 78(7): 491-497. DOI: 10.1002/pros.23492.

杨进益, 杨明州, 魏伟, 等.前列腺癌发生发展的流行病学研究进展[J].临床泌尿外科杂志, 2017, 32(9): 721-725. DOI: 10.13201/j.issn.1001-1420.2017.09.018.

YANG J Y, YANG M Z, WEI W, et al . Epidemiological study on the occurrence and development of prostate cancer[J ] . J Clin Urol, 2017, 32(9): 721-725. DOI: 10. 13201/j.issn.1001-1420.2017.09.018.

STEPHAN C, JUNG K, SEMJONOW A, et al . Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2: ERG gene fusion with the serum[-2 ] proprostate-specific antigen-based prostate health index for detection of prostate cancer[J ] . Clin Chem, 2013, 59(1): 280-288. DOI: 10.1373/clinchem.2012.195560.

LAZZERI M, HAESE A, DELA TAILLE A, et al . Serum isoform[-2 ] proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA rangeof 2-10 ng/ml: a multicentric European study[J ] . Eur Urol, 2013, 63(6): 986-994. DOI: 10.1016/j.eururo.2013.01.011.

REN S C, WANG F B, SHEN J, et al . Long non-coding RNA metastasis associated in lung adenocarcinoma transcript 1 derived miniRNA as a novel plasma-based biomarker for diagnosing prostate cancer[J ] . Eur J Cancer, 2013, 49(13): 2949-2959. DOI: 10.1016/j.ejca.2013.04.026.

FADARE O, ZHAO C Q, KHABELE D, et al . Comparative analysis of Napsin A, alpha-methylacyl-coenzyme A racemase (AMACR, P504S), and hepatocyte nuclear factor 1 beta as diagnostic markers of ovarian clear cell carcinoma: an immunohistochemical study of 279 ovarian tumours[J ] . Pathology, 2015, 47(2): 105-111. DOI: 10.1097/PAT.0000000000000223.

MARTÍNDELA FUENTE L, MALANDER S, HARTMAN L, et al . Claudin-4 expression is associated with survival in ovarian cancer but not with chemotherapy response[J ] . Int J Gynecol Pathol, 2018, 37(2): 101-109. DOI: 10.1097/PGP.0000000000000394.

CARTERH B, ALBERTSENP C, BARRYM J, et al . Early detection of prostate cancer: AUA Guideline[J ] . J Urol, 2013, 190(2): 419-426. DOI: 10.1016/j.juro.2013.04.119.

JAIN D, GUPTA S, MARWAH N, et al . Evaluation ofrole of alpha-methyl acyl-coenzyme A racemase/P504S and high molecular weight cytokeratin in diagnosing prostatic lesions[J ] . J Cancer Res Ther, 2017, 13(1): 21-25. DOI: 10.4103/0973-1482.206239.

YEVGLEVSKIS M, LEEG L, SUN J, et al . A study on the AMACR catalysed elimination reaction and its application to inhibitor testing[J ] . Org Biomol Chem, 2016, 14(2): 612-622. DOI: 10.1039/c5ob01541c.

KAWANAMI T, TANAKA T, HAMAGUCHI Y, et al . Selective androgen receptor modulator S42 suppresses prostate cancer cell proliferation[J ] . Endocrinology, 2018, 159(4): 1774-1792. DOI: 10.1210/en.2018-00099.

CUIY F, LIUA H, AND Z, et al . Claudin-4 is required for vasculogenic mimicry formation in human breast cancer cells[J ] . Oncotarget, 2015, 6(13): 11087-11097. DOI: 10.18632/oncotarget.3571.

BHATA A, AHMAD R, UPPADAS B, et al . Claudin-1 promotes TNF-α-induced epithelial-mesenchymal transition and migration in colorectal adenocarcinoma cells[J ] . Exp Cell Res, 2016, 349(1): 119-127. DOI: 10.1016/j.yexcr.2016.10.005.

TOKUHARA Y, MORINISHI T, MATSUNAGA T, et al . Nuclear expression of claudin-3 in human colorectal adenocarcinoma cell lines and tissues[J ] . Oncol Lett, 2018, 15(1): 99-108. DOI: 10.3892/ol.2017.7281.

ROMANOV V, WHYARDT C, WALTZERW C, et al . A claudin 3 and claudin 4-targeted Clostridiumperfringens protoxin is selectively cytotoxic to PSA-producing prostate cancer cells[J ] . Cancer Lett, 2014, 351(2): 260-264. DOI: 10.1016/j.canlet.2014.06.009.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

胰腺癌组织中硫酸软骨素蛋白多糖4的表达及其临床意义

食管鳞癌及癌前病变组织中紧密连接蛋白claudin3和4的表达及临床病理意义

DNA损伤修复基因以及TS、β-tubulinⅢ在骨肉瘤中的表达及其与临床病理的关系

XIAP、c-jun在肺癌组织中的表达及其意义

Claudin-3在胃腺癌的表达及预后意义